Joseph Benesch - Journey Medical Interim Controller
| DERM Stock | USD 5.37 0.17 3.27% |
Executive
Joseph Benesch is Interim Controller of Journey Medical Corp
| Age | 57 |
| Address | 9237 East Via de Ventura Boulevard, Scottsdale, AZ, United States, 85258 |
| Phone | 480 434 6670 |
| Web | https://journeymedicalcorp.com |
Latest Insider Transactions
Joseph Benesch Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Benesch against Journey Medical stock is an integral part of due diligence when investing in Journey Medical. Joseph Benesch insider activity provides valuable insight into whether Journey Medical is net buyers or sellers over its current business cycle. Note, Journey Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Journey Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Benesch over three months ago Disposition of 9324 shares by Joseph Benesch of Journey Medical at 5.47 subject to Rule 16b-3 | ||
Joseph Benesch over three months ago Disposition of 4055 shares by Joseph Benesch of Journey Medical at 5.4 subject to Rule 16b-3 | ||
Joseph Benesch over six months ago Sale by Joseph Benesch of 2450 shares of Journey Medical |
Journey Medical Management Efficiency
The company has return on total asset (ROA) of (0.1733) % which means that it has lost $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2958) %, meaning that it created substantial loss on money invested by shareholders. Journey Medical's management efficiency ratios could be used to measure how well Journey Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -0.07. In addition to that, Return On Capital Employed is likely to drop to -0.06. At this time, Journey Medical's Intangible Assets are very stable compared to the past year. As of the 25th of November 2024, Intangibles To Total Assets is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 16.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carl MD | Aquestive Therapeutics | 54 | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Ananth Krishnan | Aurora Cannabis | N/A | |
| Ernest Toth | Aquestive Therapeutics | 65 | |
| Marilyn Carlson | Evoke Pharma | 76 | |
| Jerad Seurer | Avadel Pharmaceuticals PLC | 51 | |
| Kenneth Marshall | Aquestive Therapeutics | 65 | |
| Jonathan Page | Aurora Cannabis | 55 | |
| William CPA | Organogenesis Holdings | N/A | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| MBA MD | Aquestive Therapeutics | 66 | |
| Neil Belot | Aurora Cannabis | N/A | |
| Alex Miller | Aurora Cannabis | N/A | |
| Robert Cavorsi | Organogenesis Holdings | 45 | |
| Angie Woods | Avadel Pharmaceuticals PLC | N/A | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Mark Elrod | Avadel Pharmaceuticals PLC | N/A | |
| Lori Schick | Aurora Cannabis | N/A | |
| Simona CPA | Aurora Cannabis | 52 | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
Management Performance
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.17 |
Journey Medical Corp Leadership Team
Elected by the shareholders, the Journey Medical's board of directors comprises two types of representatives: Journey Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Journey. The board's role is to monitor Journey Medical's management team and ensure that shareholders' interests are well served. Journey Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Journey Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Lindsay Rosenwald, Executive Chairman | ||
| Robyn Hunter, Treasurer Sec | ||
| Ernest Galvan, VP Strategy | ||
| Joseph Benesch, Interim Controller | ||
| Claude Maraoui, President, Founder | ||
| Robert Nevin, Chief Officer | ||
| Andrew Zwible, Vice Operations | ||
| Ramsey Alloush, General Secretary | ||
| Jaclyn Jaffe, Senior Operations |
Journey Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Journey Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 109.54 M | ||||
| Shares Outstanding | 14.89 M | ||||
| Shares Owned By Insiders | 30.47 % | ||||
| Shares Owned By Institutions | 14.56 % | ||||
| Number Of Shares Shorted | 60.75 K | ||||
| Price To Earning | (9.50) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Journey Medical Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Journey Medical. If investors know Journey will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Journey Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Revenue Per Share 2.921 | Quarterly Revenue Growth (0.58) | Return On Assets (0.17) | Return On Equity (1.30) |
The market value of Journey Medical Corp is measured differently than its book value, which is the value of Journey that is recorded on the company's balance sheet. Investors also form their own opinion of Journey Medical's value that differs from its market value or its book value, called intrinsic value, which is Journey Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Journey Medical's market value can be influenced by many factors that don't directly affect Journey Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Journey Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Journey Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Journey Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.